S. Usmani

发表

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response

B. Brownstein, G. Garcia-Manero, H. Loferer, 2016 .

A Genomic Signature Predicting Venetoclax Treatment Response in AML Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing: A Beat AML Project Study

B. Druker, C. Tognon, J. Tyner, 2016 .